title: [Oral candidiasis in HIV-seropositive patients and AIDS cases. Clinical, mycological and therapeutical aspects].
abstract: A prospective study to identify clinical and mycological aspects of oral candidiasis including a therapeutic trial for 4 drugs-2 topical (chlotrimazole and nistatine) and 2 systemic (itraconale and ketoconazole) was performed on 97 HIV adult patients from March 2003 to June 2004. Average age was 34.97 years, being males and heterosexual behaviour predominant. The pseudomembranous clinical form of presentation prevailed in 93.8% of cases, with accompanying symptoms like pain, burning sensation and difficult swallowing in addition to extensive lesions. Candida albicans was the most frequently isolated species both in swabs taken at the beginning (92%) and at the end of the treatment schedules applied to patients who did not succeed in mycological cure (89.4%). Treatment schemes had positive results from the clinical viewpoint in 91.8% of cases with improvement or total remission of symptoms and signs, and in 51.6% of mycological curing. There were no statistically significant differences of clinical and mycological responses between topical and systemic treatments. The above-mentioned allowed recommending a more extensive use of local treatment in the studied population because of their benefits for the patients.
authors: Lazprimt Grupo Médico S.A. Puebla, México, Instituto de Medicina Tropical Pedro Kouri.
authors: Luz Marina
authors: LM
authors: Prieto Santa Anna
authors: Maria Teresa
authors: MT
authors: Illnait Zaragozi
authors: Edna G
authors: EG
authors: Ramos Rodallegas
authors: Bonfilio
authors: B
authors: Lazcano Herrero
authors: Norma
authors: N
authors: Márquez Sánchez
authors: Nereyda
authors: N
authors: Cantelar de Francisco
authors: Julián
authors: J
authors: Manzur Katriba
authors: Gerardo
authors: G
authors: Martínez Machin
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D000163:Acquired Immunodeficiency Syndrome / Q000453:epidemiology; D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D002175:Candida / Q000145:classification / Q000302:isolation & purification; D002180:Candidiasis, Oral / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D003022:Clotrimazole / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006679:HIV Seropositivity / Q000453:epidemiology*; D006801:Humans; D017964:Itraconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D007654:Ketoconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008800:Mexico / Q000453:epidemiology; D008875:Middle Aged; D009761:Nystatin / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D012307:Risk Factors; D012725:Sexual Behavior; D016037:Single-Blind Method; D013045:Species Specificity; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D009761:Nystatin; D017964:Itraconazole; D003022:Clotrimazole; D007654:Ketoconazole